Epacadostat in Combination with Ppembrolizumab demonstrates Durable Responses in Patients with Advanced Melanoma
The combination drug was also well-tolerated. The most common TAEs were fatigue (39%), rash (33%), pruritus (27%), and arthralgia (16%). Grade ≥3 TRAEs were observed in 17% patients; the most common were increased lipase (n=4), rash (n=3), and increased amylase (n=2). Three patients discontinued for reasons of treatment-related adverse events, but there were no treatment-related deaths.
The abstract can be accessed on the ESMO Congress website at http://esmo.org/Conferences/ESMO-2017-Congress
Updated data from ECHO-202 will be highlighted in an oral presentation on 09th Sept, 2017 at the ESMO 2017 Congress in Madrid, Spain. The manufacturer, Incyte will also host an investor conference call and webcast at 17:00 CET (11:00 a.m. ET) on 9 September 2017.